Over the last 12 months, Rhythm Pharmaceuticals insiders reported no purchases and 17 sales totaling $41.3M across SEC Form 4 filings. 94% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Meeker David PPresident and CEO · O·D | ▼ Sale | 50,000 | $102.67 | $5.1M | -17.3% | plan · 5 tranches |
| Aug 31, 2026 | Smith Hunter CChief Financial Officer · O | ▼ Sale | 62,774 | $105.46 | $6.6M | -35.5% | plan · 3 tranches |
| Aug 13, 2026 | Shulman JosephChief Technical Officer · O | ▼ Sale | 5,079 | $119.75 | $608K | -24.2% | plan |
| Aug 13, 2026 | Garfield AlastairChief Scientific Officer · O | ▼ Sale | 7,763 | $117.57 | $913K | -77.2% | plan · 4 tranches |
| Aug 13, 2026 | Lee Jennifer KaydenEVP, Head of North America · O | ▼ Sale | 75,834 | $117.38 | $8.9M | -100% | plan |
| Aug 12, 2026 | Mazabraud YannEVP, Head of International · O | ▼ Sale | 57,000 | $116.15 | $6.6M | -50.6% | plan · 6 tranches |
| Jun 22, 2026 | TETRAULT LYNN A.D | ▼ Sale | 37,000 | $100.32 | $3.7M | -84.1% | plan |
| Mar 4, 2026 | German Christopher PaulCorporate Controller & CAO · O | ▼ Sale | 5,614 | $89.56 | $503K | -97.2% | — |
| Feb 19, 2026 | Smith Hunter CChief Financial Officer · O | ▼ Sale | 7,954 | $101.31 | $806K | -6.7% | plan · 9 tranches |
| Feb 12, 2026 | Smith Hunter CChief Financial Officer · O | ▼ Sale | 7,071 | $100.21 | $709K | -5.6% | plan · 10 tranches |
| Feb 5, 2026 | Smith Hunter CChief Financial Officer · O | ▼ Sale | 6,628 | $106.03 | $703K | -5% | plan · 4 tranches |
| Dec 11, 2025 | Cramer Pamela J.Chief Human Resources Officer · O | ▼ Sale | 3,350 | $111 | $372K | -13.9% | plan |
| Nov 20, 2025 | Cramer Pamela J.Chief Human Resources Officer · O | ▼ Sale | 3,350 | $105 | $352K | -13.9% | plan |
| Nov 10, 2025 | Cramer Pamela J.Chief Human Resources Officer · O | ▼ Sale | 22,866 | $99 | $2.3M | -52.3% | plan · 2 tranches |
| Oct 30, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 9,748 | $115.24 | $1.1M | -53.4% | plan |
| Oct 28, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 2,815 | $115.01 | $324K | -24.9% | plan |
| Oct 16, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 14,437 | $112.03 | $1.6M | -62.9% | plan · 3 tranches |
| Sep 2, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 16,781 | $105.3 | $1.8M | -66.4% | plan |
| Aug 21, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 4,188 | $100.07 | $419K | -33% | plan |
| Aug 13, 2025 | Smith Hunter CChief Financial Officer · O | ▼ Sale | 28,088 | $96.29 | $2.7M | -19.4% | plan · 2 tranches |
| Aug 12, 2025 | German Christopher PaulCorporate Controller & CAO · O | ▼ Sale | 1,500 | $95 | $143K | -61.9% | plan |
| Aug 11, 2025 | Shulman JosephChief Technical Officer · O | ▼ Sale | 3,984 | $90.08 | $359K | -31.9% | plan |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Rhythm Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RYTM feed.